While most companies working in the RNAi drugs field have been able to secure the money needed to maintain operations, a number of players in the space have bowed out under unfavorable circumstances.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
